Clinical trials: Alzheimer or Mild Cognitive Impairment
- Condition Alzheimer or Mild Cognitive Impairment
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Alzheimers Disease
A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease
The primary purpose of this study is to evaluate the efficacy of LEQEMBI in participants with early Alzheimer's disease (AD) indicated per Canada Product Monograph (APOE4 non-carriers and heterozygotes; indicated population)…
- Trial name
- NCT07864623
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Eisai Inc.